PatientsVille.com Logo


Bladder Cancer Medical Research Studies

Up-to-date List of Bladder Cancer Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Bladder Cancer Medical Research Studies

Rank Status Study
1 Recruiting PlasmaKinetic (PK) Button Vaporization Electrode for Treatment of Bladder Tumors
Condition: Bladder Cancer
Interventions: Device: Monopolar electrocautery loop in Transurethral resection of bladder tumors;   Device: PK Button Vaporization Electrode in transurethral resection of bladder tumors
Outcome Measures: Procedural complications;   Operative follow-up
2 Recruiting Fluorescence Cystoscopy and Optimized MMC in Recurrent BLADDER CANCER (FinnBladder 9)
Condition: Bladder Cancer
Interventions: Procedure: white light TUR-BT;   Procedure: blue light TUR-BT;   Drug: optimized MMC;   Drug: single immediate chemotherapy instillation
Outcome Measures: bladder cancer recurrence rate;   Bladder cancer progression;   Treatment failure;   mortality
3 Recruiting Biomarker Identification for BLADDER CANCER Patients
Condition: Bladder Cancer
Intervention: Procedure: Sample Collection
Outcome Measure: Identify novel biomarkers for bladder cancer
4 Recruiting Evaluation of Non-Invasive Assay(s) for the Detection of BLADDER CANCER
Conditions: Bladder Cancer;   Cancer;   Bladder Neoplasms;   Urinary Bladder Cancer
Outcome Measure: To evaluate the utility of emerging technologies in the detection of bladder tumor cells using non-invasive approaches utilizing voided urine samples.
5 Unknown  Selenium in Preventing Cancer Recurrence in Patients With BLADDER CANCER
Condition: Bladder Cancer
Interventions: Dietary Supplement: selenium;   Other: placebo
Outcome Measures: Effect of selenium in preventing the recurrence of BLADDER CANCER;   Effect of selenium on the recurrence of BLADDER CANCER, in terms of histological type, number, and size
6 Not yet recruiting Detection of K14 in BLADDER CANCER With a Non Invasive Technique
Condition: Bladder Cancer
Outcome Measure: Keratin 14
7 Unknown  Genetic Susceptibility to BLADDER CANCER
Conditions: Bladder Cancer;   Healthy
Intervention: Other: Specimens, personal and follow-up telephone interviews
Outcome Measures: To assess both cohorts, two mutagen sensitivity susceptibility assays that quantifies the number of lymphocytic chromatid breaks induced by in vitro exposure to bleomycin and the number of breaks induced by in vitro exposure to a tobacco carcinogen.;   To determine in both cohorts, the frequencies of polymorphisms in those genes that regulate the metabolism of carcinogens in tobacco smoke.;   To explore the associations between the cytogenetic, molecular components and epidemiologic covariates (age, sex, ethnicity, cigarette smoking status, alcohol use, dietary intake, and family history of cancer) in risk of BLADDER CANCER.
8 Recruiting Improving Clinical Staging for Muscle Invasive BLADDER CANCER Through Molecular Profiling and Improved Imaging
Condition: Bladder Cancer
Interventions: Procedure: Tissue Biopsy;   Procedure: Magnetic Resonance Imaging (MRI)
Outcome Measure: Detection Improvement of Cancer Outside of the Bladder
9 Recruiting Radiation Therapy and Chemotherapy in Treating Patients With Stage I BLADDER CANCER
Condition: Bladder Cancer
Interventions: Drug: cisplatin;   Drug: fluorouracil;   Drug: mitomycin C
Outcome Measures: Rate of freedom from radical cystectomy at 3 years;   Rate of freedom from radical cystectomy at 5 years;   Rate of freedom from the development of distant disease progression at 3 and 5 years;   Rate of freedom from progression of bladder tumor to stage T2 or greater at 3 and 5 years;   Disease-specific survival at 5 years;   Overall survival;   Incidence of adverse events as assessed by Common Toxicity Criteria for Adverse Effects (CTCAE), v3.0;   Recurrence rate of any local bladder tumor;   Descriptive analysis for American Urological Association symptom score at baseline and at 3 years
10 Recruiting Clinical Trial Using Bipolar Technology for Transurethral Resection of Bladder Tumor
Condition: Urinary Bladder Tumor
Interventions: Device: Monopolar diathermy;   Device: Bipolar diathermy
Outcome Measures: Muscle sampling rate;   Incidence of TUR syndrome;   Recurrence rate of bladder cancer
11 Recruiting Chemoradiation for Bladder Preservation in Patients With Muscle Invasive Bladder Carcinoma After Complete Response to Neoadjuvant Chemotherapy
Conditions: Bladder Cancer;   Bladder Carcinoma;   Transition Cell Cancer;   Muscle Invasive Bladder Carcinoma
Interventions: Procedure: Transurethral Resection of the Bladder Tumor & Cystoscopy;   Drug: Cisplatin;   Drug: Gemcitabine;   Radiation: Intensity Modulated Radiation Therapy;   Behavioral: Quality of Life Questionnaires;   Genetic: Urine Collection for Molecular Analysis;   Genetic: Blood Collection for Molecular Analysis
Outcome Measures: Percentage of patients experiencing failure free survival with intact bladder (FFSIB);   Percentage of patients experiencing failure free survival at two years;   Number of patients experiencing acute and late grad 2 or higher treatment related adverse events.
12 Recruiting Risk of BLADDER CANCER in Type 2 Diabetes Patients With Pioglitazone Therapy "PROBE"
Condition: Bladder Cancer
Intervention: Drug: Pioglitazone
Outcome Measure: Bladder cancer rate
13 Recruiting Neoadjuvant Gemcitabine and Fractionated, Weekly Cisplatin For Muscle Invasive BLADDER CANCER and Patients Not Candidates For High Dose Cisplatin
Conditions: Invasive Bladder Cancer;   Bladder Cancer
Intervention: Drug: Gemcitabine and fractionated cisplatin (combination treatment)
Outcome Measures: Pathologic complete response rate of neoadjuvant gemcitabine and fractionated cisplatin for patients with muscle invasive BLADDER CANCER whom are not candidates for high dose cisplatin.;   Types of toxicities participants experience with neoadjuvant gemcitabine and fractionated cisplatin for patients with BLADDER CANCER.
14 Recruiting PET/MRI and Biomarkers in BLADDER CANCER
Condition: Bladder Cancer
Intervention: Device: MRI/acetate-PET imaging
Outcome Measures: staging accuracy of PET/MRI in bladder cancer;   Accuracy of PET/MRI to estimate response to neoadjuvant chemotherapy
15 Unknown  NMP22 Provides Improved Sensitivity in Detecting BLADDER CANCERs.
Condition: Bladder Cancer
Intervention: Device: Use of Nuclear Matrix Protein 22 Urine sample kit to determine BLADDER CANCER
Outcome Measure:
16 Recruiting Value of Immediate Post-operative Intravesical Epirubicin in Intermediate&High Risk Non Muscle Invasive BLADDER CANCER
Condition: Carcinoma of Urinary Bladder, Superficial
Intervention: Drug: Epirubicin
Outcome Measures: Recurrence, progression and/or death from cancer.;   Number of Participants with Adverse Events as a Measure of Safety and Tolerability
17 Unknown  Standard Surgery or Minimal-Access Surgery in Treating Patients With BLADDER CANCER
Condition: Bladder Cancer
Interventions: Other: questionnaire administration;   Procedure: quality-of-life assessment;   Procedure: robot-assisted laparoscopic surgery;   Procedure: therapeutic conventional surgery;   Procedure: therapeutic laparoscopic surgery
Outcome Measures: Percentage of patients who consent to be randomized;   Potential barriers to randomization via semistructured qualitative interviews with patients who consent to registration and do not accept randomization;   Potential factors relating to non-registration of patients who are eligible for inclusion but have not been registered based on review of anonymous screening logs;   Safety and efficacy;   Quality of life data measuring return to normal activities (physical, social, and occupational)
18 Unknown  Efficacy Study of a Urine DEK ELISA for Diagnosis of BLADDER CANCER
Conditions: Hematuria;   Dysuria;   Bladder Cancer
Outcome Measure:
19 Not yet recruiting Evaluation the Treatment of Tamoxifen of Low/Intermediate Risk Bladder Tumors
Condition: Bladder Cancer
Intervention: Drug: Tamoxifen Citrate
Outcome Measure: Evaluate the efficacy for treatment of low/intermediate- risk bladder tumors, assessing for the clinical response of the marker lesion
20 Recruiting A Laser Detection for BLADDER CANCER by (Photodynamic) Spectra of Urine
Condition: Transitional Cell Carcinoma of the Bladder
Intervention: Drug: Amino levulinic Acid
Outcome Measures: Urine spectral profile after four hours;   Urine spectral profile after eight hours

These studies may lead to new treatments and are adding insight into Bladder Cancer etiology and treatment.

A major focus of Bladder Cancer research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.

Discuss Bladder Cancer